Apogenix AG

Apogenix develops innovative immuno-oncology therapeutics for the treatment of cancer and other malignant diseases. The company has built a promising pipeline of drug candidates that target different tumor necrosis factor (TNF) superfamily-dependent signaling pathways, thereby restoring the anti-tumor immune response.

Checkpoint inhibitor asunercept, Apogenix’s lead immuno-oncology candidate, is being developed for the treatment of solid tumors and malignant hematological diseases. Asunercept has been shown to prolong overall survival in a phase II trial in recurrent glioblastoma and has demonstrated hematological improvements in a phase I trial in myelodysplastic syndromes. In 2017, asunercept received PRIME (PRIority MEdicines) designation by the European Medicines Agency (EMA) for the treatment of glioblastoma.

Apogenix has also developed a proprietary technology platform for the construction of novel hexavalent TNF superfamily receptor agonists (HERA-ligands) for wide use in oncology. Due to their specific molecular structure, these HERA-ligands have clear advantages over other biotherapeutics, such as antibodies. Apogenix’ HERA-ligands have shown strong anti-tumor efficacy in vitro and in vivo, with a benign safety profile. Apogenix is utilizing its technology platform to develop CD40, CD27, GITR, HVEM, 4-1BB, and OX40 receptor agonists for cancer immunotherapy.

Further information on the websites of BIOPRO Baden-Württemberg: